Lava Therapeutics B.V. (spin-off Amsterdam UMC, location VUmc) announced that it has entered into a research and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover and develop novel bispecific antibodies to gamma-delta T cells for the treatment of cancer. The collaboration was facilitated by Johnson & Johnson Innovation.
“We are excited to enter into this collaboration with Janssen, a global innovator and leader in the development of new medicines,” said Stephen Hurly, chief executive officer of Lava Therapeutics. “We strongly believe in the strength of our bispecific gamma-delta T cell engager platform and are committed to creating highly potent, target-specific therapeutics with increased durability and safety over current T cell-based approaches.”
Under the terms of the agreement, Lava Therapeutics will perform discovery and product development activities, and is eligible to receive an undisclosed financial package consisting of an upfront payment and potential development and commercial milestones, and future tiered royalties.
Lava Therapeutics, B.V., is developing a proprietary bispecific antibody platform that engages gamma-delta T cells for the treatment of hematological and solid cancers. The company’s first-in-class immuno-oncology approach activates Vγ9Vδ2 T cells upon binding to membrane-expressed tumor targets. Lava was founded in 2016 based on intellectual property originating from the Amsterdam University Medical Center, and is backed by Lupus Ventures, Biox Biosciences, Versant Ventures, Gilde Healthcare and MRL Ventures Fund. The company has established a highly experienced antibody research and development team located in Utrecht, the Netherlands (headquarters) and Philadelphia. For more information, please visit www.lavatherapeutics.com.
The Dutch company NoWa Kitchen presented its newest kitchen featuring only bio-based materials and a sustainable cradle-to-cradle design. A key enabler for the kitchen are plant-based polymers and materials brought to market by the University of Amsterdam’s spin-off company Plantics, stemming from a discovery made by chemists at the Van ‘t Hoff Institute for Molecular […]News
In the race to a sustainable and healthy future, the benefits of biotech innovations are key. Both biotech academics and entrepreneurs must continue to turn knowledge into social and commercial successes. Nettie Buitelaar, Biotech Booster ‘s CEO, answers five questions in order to tell us how to boost new biotech innovations. The Biotech Booster programme […]News
Innoseis recently marked a significant milestone – a decade of pioneering work in seismic sensing. The company, a spin-off of VU and the National Institute for Subatomic Physics, Nikhef, uses precision motion sensing for seismic and guidance applications. We sat down with CEO Mark Beker and CTO Jo van den Brand to learn more about […]News